This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

National Survey on Dyslipidemic Patients (PRYSME)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 18, 2008
Last updated: August 4, 2009
Last verified: August 2009
The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). [ Time Frame: Once ]

Enrollment: 3655
Study Start Date: June 2008
Study Completion Date: January 2009

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First three consecutive dyslipidemic patients seen by GP

Inclusion Criteria:

  • Diagnosis of dyslipemia made less than 2 years
  • Treated by a lipid-lowering drug
  • Agree to take part in the survey

Exclusion Criteria:

  • Patient included in a clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00701402

  Show 1207 Study Locations
Sponsors and Collaborators
Study Director: Alain Castaigne AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00701402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/9
Study First Received: June 18, 2008
Last Updated: August 4, 2009

Keywords provided by AstraZeneca:
time to lipid-lowering drug implementation
dyslipidemic patients

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on August 23, 2017